We believe that all oncology drugs will have a digital companion in the future. This is for a few reasons: Cancer treatments often cause side effects that need to be managed and monitored carefully. Patients need to be empowered to manage their treatment on a daily basis, receiving personalised support and guidance – which will have a big effect on the patients quality of life. Improved treatment adherence will also lead to improved outcomes. And for pharma companies, showing outcomes in real world will become a condition for reimbursement – it’s just a question of when. Voluntis positioning at the forefront of the rapidly growing digital therapeutics sector is perfectly aligned with Debiopharm’s priority areas of interest.